Back to News
Market Impact: 0.35
Halozyme Therapeutics Unveils $1.05 Bln Offering Of Convertible Notes Due 2033
Source: Nasdaq
Credit & Bond MarketsCompany Fundamentals
Halozyme Therapeutics intends to offer $1.05 billion of convertible senior notes due 2033 and may grant initial purchasers a 13-day option to buy up to an additional $150 million. The financing could raise as much as $1.20 billion, strengthening liquidity but introducing potential future equity dilution and additional debt obligations.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mixed
Sentiment Score
-0.10
Ticker Sentiment
HALO-0.15
More News
- Binance seeks to shore up confidence after record $6.3 billion heist
- Why is Alstom stock down 27% today?
- Alstom shares sink 28% after outlook cut on Coradia Max execution issues
- Amgen (AMGN) Bets on MariTide to Crack $120 Billion Obesity Market
- Binance sees outflows stabilising as exchange returns online after $6.3 billion heist
- Apollo launches $11 billion private credit platform, backed by Abu Dhabi